AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

Leukemia, Myeloid, Chronic Clinical Trial

Official title:

Phase II Exploratory Study Of AG-858 Plus Gleevec™ In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec™

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00058747
• Other study ID #: C-300-01
• Status: Terminated
• Phase: Phase 2
• First received: April 11, 2003
• Last updated: September 6, 2012
• Start date: March 2003
• Est. completion date: April 2006

Study information

• Verified date: September 2012
• Source: Agenus, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase II, exploratory, open-label study of the investigational product AG-858, in patients who are cytogenetically positive after treatment with Gleevec.

The trial will consist of three independent Phase II evaluations of patient groups according to their cytogenetic status as defined in the eligibility criteria (Eligibility Criteria 4a, 4b, and 4c).

Description:

The goals of this study are to determine the following:

• To estimate the proportion of patients with a complete cytogenetic response (CCR) within each patient group

• To estimate the proportion of patients with a substantial molecular response (SMR) within each patient group

• To evaluate the frequency and severity of adverse events.

• To assess the feasibility of AG-858 production.

Other known NCT identifiers

• NCT00070395

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: April 2006
• Est. primary completion date: April 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be Philadelphia chromosome positive chronic myelogenous leukemia in first chronic phase

• Must have a complete hematologic response

• Must have received Gleevec™, IFN-a, cytarabine, busulfan, hydroxyurea, Homoharringtonine (HHT) or any combination thereof as long as the combination has been discontinued and the dosing of Gleevec™ has been stable for 6 months or greater

• Must have one of the following cytogenetic statuses:

(A) Less than a CCR after receiving Gleevec™ for at least one year at a minimum dose of 400 mg/day. A stable dose of Gleevec™ must have been maintained for the last six months prior to eligibility testing OR (B) Stable cytogenetic status without CCR (no cytogenic response or progression) in three consecutive determinations over six months while on a stable dose of Gleevec™ (at a minimum of 400mg/day) for at least 6 months OR (C) Cytogenetic progression while on a stable dose of Gleevec™ (at a minimum dose of 400mg/day)for at least 2 consecutive evaluations at least one month apart

• ECOG performance score of 0 or 1

• Must be at least 18 years old

• Not pregnant or breastfeeding and agree to use contraception during the course of the study

• No prior allogeneic bone marrow transplant or be candidates for curative BMT

• No immunodeficiency or other serious illness

• No current use of immunosuppressive medications

• No other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic

Intervention

Drug:
• Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Agenus, Inc.

Countries where clinical trial is conducted

United States,  United Kingdom, 

External Links

•   For more information regarding Gleevec™, please visit Novartis' website